Cargando...
Myopathy secondary to empagliflozin therapy in type 2 diabetes
SUMMARY: Sodium/glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycaemic agents that are increasingly used in the management of type 2 diabetes mellitus (T2DM). They are now recommended as second-line pharmacotherapy (in conjunction with metformin) in patients with type 2 diabetes an...
Gardado en:
| Publicado en: | Endocrinol Diabetes Metab Case Rep |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Bioscientifica Ltd
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7159254/ https://ncbi.nlm.nih.gov/pubmed/32478668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-20-0017 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|